Cannabis stocks news - daily news on stocks on CSE, TSX, TSXV, OTC, NASDAQ and NYSE from InvestorIdeas.com
Thursday 22 April 2021
#Cannabis #Stock News: Phyto Extractions(TM) (CSE: $XTRX.C) (Frankfurt:D2EP) Announces Health Canada R&D License Addendum; @adastra_labs
#Cannabis #Stock News: Phyto Extractions(TM)
(CSE: $XTRX.C) (Frankfurt:D2EP) Announces Health Canada R&D License
Addendum; @adastra_labs
LANGLEY,
BC - April 22, 2021 (Investorideas.com Newswire) Phyto Extractions Inc.
(formerly, Adastra Labs Holdings Ltd.) (CSE:XTRX) (Frankfurt:D2EP)
("Phyto Extractions™" or the "Company") is pleased to
announce that it has received its R&D license addendum in Adastra Labs Inc.
that will permit some limited human testing by licensed researchers
administering or distributing cannabis to human research subjects using
cannabis obtained from a holder of a licence for processing in the final form
of cannabis.
Read this new,
featuring XTRX in full at https://www.investorideas.com/CO/XTRX/news/2021/04221RD-License-Addendum.asp
R&D
License
This
R&D license addendum will permit the Company to conduct in-house human
testing for taste of various cannabis products for assessment of taste, sights,
smell, or touch of cannabis.
“We
look forward to initiating human-studies and generating valuable consumer-based
data to support our product development pipeline and continue delivering
high-quality efficacious cannabis products to Canadians.” Stated Dr. Kyle
Boniface, PhD.”
About
Phyto Extractions™
Phyto
Extractions™ is an agricultural-scale cannabis extraction, distillation and
product manufacturer located in Langley, BC at its co-located Health Canada
Licensed Standard Processing (extraction and products, no cultivation), Sales
(extracts, topicals, and edibles), and R&D through Adastra Labs Inc. and
Analytical Testing Laboratory through Chemia Analytics Inc.
ON
BEHALF OF THE BOARD
ADASTRA
LABS HOLDINGS LTD.
Contact:
J. Scott Munro, President, CEO & Director (Chairman)
Phone:
(778) 715-5011
Email:
scott@adastralabs.ca
Forward-Looking Information:
This news release includes forward-looking
information within the meaning of Canadian securities legislation, concerning
the business of the Company. Forward-looking information is based on certain
key expectations and assumptions made by the management of the Company.
Although the Company believes that the expectations and assumptions on which
such forward-looking information is based are reasonable, undue reliance should
not be placed on the forward-looking information because the Company can give
no assurance that they will prove to be correct. Forward-looking information in
this news release includes statements with respect of the proposed name change,
proposed consolidation, the closing of the private placement and the use of
proceeds thereof. There are numerous risks and uncertainties that could cause
actual results and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i) adverse
market conditions; (ii) risks inherent in the cannabis extraction sector in
general; (iii) inability to close the private placement for any reason, or in
the amounts expected by the Company; and (iv) other factors beyond the control
of the Company.
Actual results and future events could differ
materially from those anticipated in such information. These and all subsequent
written and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the Company does
not intend to update these forward-looking statements.
The CSE has not reviewed or approved of any
contents of this news release.
SOURCE:
Phyto Extractions Inc.
Phyto
Extractions Inc. (CSE:XTRX) (Frankfurt:D2EP) is a featured Cannabis stock on
Investorideas.com
Disclaimer/Disclosure:
Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: XTRX is a featured cannabis stock on
Investorideas.com and the cannabis potcast effective April 14 More disclaimer
info: https://www.investorideas.com/About/Disclaimer.asp Learn more
about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global
investors must adhere to regulations of each country. Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get more Cannabis Stock Investor Ideas - news, articles, podcasts and
stock directories
#Pet #Stocks in the #Stock News: Link Reservations Inc / LinkResPet (OTC: $LRSV) Developing #CBD Product To Combat #PetObesity, @res_pet
#Pet #Stocks in the #Stock News: Link
Reservations Inc / LinkResPet (OTC: $LRSV) Developing #CBD Product To Combat #PetObesity,
@res_pet
London, UK – April 22, 2021 - Breaking CBD stock news from Investorideas.com
Newswire- Link Reservations Inc. (OTC: LRSV), a provider of
wellness and cannabidiol (CBD) products for both humans and pets, announces it is exploring
the development of a new LinkResPet CBD product to aid pets
dealing with obesity and weight problems. The new tincture will promote fat
loss and increase energy levels in animals.
Read this news,
featuring LRSV in full at https://www.investorideas.com/news/2021/cannabis/04221LRSV-CBD-Pet.asp
Obesity and weight problems are an existing issue in people’s lives,
whether they hear about it or encounter it in their lives. However it is not
exclusively a human problem, our pets are suffering too. Just
in North America, approximately 25-30% of the general canine population is
obese, with 40-45% of dogs aged 5-11 years old weighing in higher than normal. As with humans,
the additional weight can increase the risks of health issues in the animals’
lives – from a shortened life expectancy to problems like diabetes, kidney
disease and arthritis – and owners whose pets carry additional weight are
likely to see their pets’ quality of life degrade.
On a mission to combat this, LinkResPet is exploring the development of
a CBD solution to help obese and overweight pets get back to a healthy weight. Intended to be used as a supplement to a restricted
calorie diet, the specialized weight-loss promoting product will have a CBD
base and be 100% natural.
Different ingredients are being considered but the end product will be aimed at
helping metabolise fat and create further heat and energy.
Rene Lauritsen, CEO at Link Reservations Inc. commented: “Our main goal
has always been to improve and maintain the quality of life of pets through
natural solutions. Obesity is a problem that affects more than half of US pets
and as such it is of high priority for us. We are researching the different
options and aim to have a 100% natural product ready for production soon. It is
a new venture for us, in that we are taking the benefits of CBD and advancing
them through other functional ingredients to tackle specific pet health issues,
and we are incredibly excited to see what the final product looks like. I look
forward to updating our shareholders with any further developments as we reach
each milestone in the product strategy.”
LinkResPet already markets CBD products for dogs, cats and horses. Its sister brand, DailyLifeCBD offers CBD & functional mushroom wellness
products for people.
The weight loss product is currently in research stage with the aim of
launching later in the year.
About Link Reservations Inc.
Link Reservations Inc is a CBD and
wellness product provider dedicated to improving the health and life conditions
of both people and pets worldwide. Its trades through its two brands;
LinkResPet and DailyLifeCBD. LinkResPet develops and markets hemp-based CBD
products for cats, dogs and horses. DailyLifeCBD provides everyday hemp based
CBD wellness products for people. The Company has operations in both the US and
Europe.
Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking"
statements within the meaning of the Safe Harbor provisions of Federal
Securities Laws, as that term is defined in section 27a of the United States
Securities Act of 1933, as amended, and section 21e of the United States
Securities Exchange Act of 1934, as amended. Statements in this document, which
are not purely historical, are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions regarding the
future. Investors are cautioned that such statements are based upon assumptions
that in the future may prove not to have been accurate and are subject to
significant risks and uncertainties, including the future financial performance
of the Company. Although the Company believes that the expectations reflected
in its forward-looking statements are reasonable, it can give no assurance that
such expectations or any of its forward-looking statements will prove to be
correct. Readers are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date of this release, and
the Company undertakes no obligation to update publicly any forward-looking
statements to reflect new information, events, or circumstances after the date
of this release except as required by law.
Linkreservations Inc
400 Thames Valley Park Drive
Reading Berkshire RG6 1 PT
United Kingdom
Phone: +44 330 808 0897
Paid News -Disclaimer/Disclosure: Investorideas.com is a digital
publisher of third party sourced news, articles and equity research as well as
creates original content, including video, interviews and articles. Original
content created by investorideas is protected by copyright laws other than
syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. Disclosure : this news release featuring LRSV is a paid for news
release on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing
your news release and our other news services on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Please
read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news alerts
at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
Investors can trade these stocks and other ideas on
our site using our list of top stock trading apps including Robinhood, Acorn,
Stash and others.
Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories
Wednesday 21 April 2021
Investor Ideas #Potcasts 555, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C) (TSX: $FAF.TO) (CSE: $AION.C) (CSE: $IPOT.C) (OTC: $ISCNF) (TSX: $WEED.TO) (NASDAQ: $CGC)
Investor Ideas #Potcasts
555, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C) (TSX: $FAF.TO)
(CSE: $AION.C) (CSE: $IPOT.C) (OTC: $ISCNF) (TSX: $WEED.TO) (NASDAQ: $CGC)
Delta, Kelowna, BC, April 21, 2021 (Investorideas.com Newswire) www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/042121-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/04211XTRX-FAF-AION-IPOT-ISCNF-WEED-CGC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com "Potcast"
featuring cannabis news, stocks to watch as well as insights from thought
leaders and experts.
Today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
In
today’s podcast we look at a few private and public company announcements.
Fire
& Flower Holdings Corp. (TSX:
FAF)
(OTCQX:
FFLWF) and its indirect wholly-owned subsidiary Hifyre Inc.,
today announced the milestone achievement of 250,000 Spark
PerksTM members across the Fire & Flower retail network.
Spark Perks members receive special
benefits where permitted, including: Spark Fastlane TM click-and-collect
checkout, personalized recommendations, curbside pickup, free rapid delivery,
and exclusive deals. No cannabis purchase is required to join the free program.
The Sparks Perks program is now
available across all Fire & Flower banners including Friendly Stranger,
Happy Dayz and Hotbox and delivers personalized product recommendations to
members.
"A core metric in our business
is lifetime customer value and the cost of customer acquisition. We believe
Spark Perks customers have the highest lifetime customer value in the industry
through their larger basket sizes, more frequent visits and the diversity of
products they consume," said Trevor Fencott, Chief Executive Officer of
Fire & Flower.
"While growing rapidly, we have
also focused on a low cost of customer acquisition. Although metrics such as
same store sales are important, as an evolved technology-enabled retail company
we focus on customer engagement metrics that will be critical as our platform
scales to the U.S."
Key
Metrics from the Spark Perks Program:
● Members
who order from Same Day Rapid Delivery spend 110 per cent more than non-members
and have 90 per cent larger baskets than non-members
● Members
served through Fastlane pickup spend 49 per cent more than non-members in-store
● Members
transacting in-store have 27 per cent larger basket sizes than non-members with
19 per cent more items in their baskets
The
Spark Perks program leverages the HifyreTM advanced digital retail and
analytics platform. Hifyre is the leading Canadian data and analytics platform
within the cannabis industry and recently entered into a strategic agreement
with BDS Analytics Inc. ("BDSA") to incorporate Hifyre's Canadian
digital retail and analytics into BDSA's existing online U.S.-based market
research platform. As part of the agreement, BDSA will offer Hifyre IQ Canadian
cannabis data to its U.S.-based clients and Hifyre will be able to provide U.S.
data from BDSA to its Canadian clients, allowing both companies to offer
enhanced, cross-border data to their respective consumer bases.
The
company also
announced that it will release its financial and operational
results for fourth quarter and the fiscal year of 2020 ended January 30, 2021
before financial markets open on April 27, 2021. The results will be available
on SEDAR and on the Company's website at https://fireandflower.com/investor-relations.
Following
the release of the results, Fire & Flower will host a conference call with
Trevor Fencott, President and Chief Executive Officer, and Nadia Vattovaz,
Executive Vice President, Operations and Chief Financial Officer at 8:30 a.m.
EDT on April 27, 2021. The conference call will discuss Fire & Flower's
fourth quarter and fiscal year 2020 financial and operational results and
updates on the Company's plans for fiscal year 2021.
Aion Therapeutic
Inc.
(CSE:
AION) announced
today that its proprietary and patented combinatorial
mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or
"Preparations") showed
high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer
cells, and triple-negative breast cancer cells by direct cytotoxicity.
As
shown in recently completed third-party independent and carefully controlled
3D-spheroid cell culture studies performed at BIOENSIS laboratories, these
cytotoxicity studies demonstrated direct killing of the breast cancer cells by
the Aion Mushroom Preparations, which suggests such preparations may be
effective in treating HER2+ breast cancer, ER+/PR+ breast cancer, and the very
difficult to treat triple-negative breast cancer, with each of these types of
breast cancers tested independently.
In
separate independent studies at BIOENSIS laboratories using the
Antibody-Dependent Cellular Cytotoxicity (ADCC) assay and the
Antibody-Dependent Cellular Phagocytosis (ADCP) assay, the Aion Mushroom
Preparations also demonstrated enhanced cell killing of HER2+ breast cancer
cells via stimulation of the immune system. The Preparations showed similar
effectiveness as trastuzumab, a monoclonal antibody treatment sold under the
brand name Herceptin, manufactured by Roche and is a US FDA approved medication
useful for treating HER2+ breast cancer that is either early-stage or
advanced-stage/metastatic.
Herceptin
(trastuzumab) is the leading breast cancer drug with annual global sales of
around $7 billion.1 Other FDA approved biosimilar trastuzumab products include:
Trazimera (Pfizer), Kanjinti (Amgen), Ontruzant (Merck), Herzuma (Teva), and
Ogivri (Mylan). When Aion Mushroom Preparations were combined with Trastuzumab,
there was a greater than 60% increase in the killing of HER2+ breast cancer
cells when compared to Trastuzumab used alone.
Based
on these results, Dr. Herbert A. Fritsche, Chief Science Officer of Aion
Therapeutic and former Professor and Director of Clinical Chemistry at the
University of Texas, MD Anderson Cancer Center, stated, "The extremely
exciting results obtained from these independent 3D cell culture studies suggests
that when appropriate Aion Mushroom Preparations are used together, they may
offer a dual approach to the killing of HER2+ breast cancer cells through two
separate and distinct pathways (direct cytotoxicity and antibody dependent
cytotoxicity). The significant improvement in cancer cell cytotoxicity that was
observed when the Preparations were combined with Trastuzumab warrants
immediate further investigation in breast cancer patients." Dr. Fritsche
continued, "We look forward to the next step of initiating clinical trials
of the Aion Mushroom Preparations with and without Herceptin (and other
trastuzumab biosimilars) for the treatment of HER2+ breast cancer patients as
well as the Aion Mushroom Preparations alone in ER+/PR+ breast cancer and
triple-negative breast cancer patients."
"Each
year more than 1.6 million new cases of breast cancer are diagnosed globally,
making it the most common cancer among women, and more than 500,000 women will
die of the disease," said Graham Simmonds, Executive Vice Chair and CEO of
Aion Therapeutic. He added, "We are excited that these Aion Mushroom
Preparations that have shown very encouraging initial test results will be
developed to be transformative in how women are treated globally."
Isracann
Biosciences Inc. (CSE:
IPOT) (OTC:
ISCNF) an Israel-based company focused on becoming a premier
low cost, high quality cannabis producer/distributor announced that it
has been granted a Foreign Owners Cannabis License by the Israeli Minister of
Health. This important event paves the way to conclude a number of outstanding
key partnership and regulatory considerations in preparation for commercial
operations.
In
a press release issued on March 24, 2020, Isracann announced its entry into a
joint venture (JV) agreement as part of a phased partnership of two near-term
farm operations located in Ein Hahoresh, Israel. The agreement included an
equitable sharing arrangement of both operating costs and revenue through
participatory agreements comprising construction services, growing services,
land lease agreements, IMCA licenses, and a number of sub agreements
establishing and defining the various rights of all parties. Today’s
announcement represents the removal of regulatory ownership barriers in order
to fully execute the terms of the JV plan.
The
highly sought-after foreign owners license significantly legitimizes the
Company’s presence in Israel. There are only a small number of foreign owned
sector participants who have obtained similar licencing, and Isracann is now
favourably positioned to leverage certain advantages. Ownership licensing
allows for greater access to domestic partnerships, increased participation in
state-sponsored initiatives, and enhances access to financing. It also
simplifies the Company’s ability to undertake domestic acquisitions, including
the conclusion of its planned purchase of a third-party participant in the JV
which would result in Isracann increasing its ownership position to 50%.
In
related news, the Company has concluded all requisite construction and
infrastructural installations in preparation for the commencement of planting
and subsequent production at its Hefer Valley-based Ein Hahoresh Farm. Largely
due to COVID-19 related delays, Isracann has a final regulatory hurdle to
conclude which appears to be moving closer to conclusion. Based on discussions
with our regional consultants, we are waiting for an inspection by law
enforcement officials and concurrent Ministry of Health approvals. It is our
understanding that scheduling for the inspection is imminent. Upon receipt,
Isracann will have full approval to begin planting.
Regarding
the recently announced medical cannabis import partnership LOI, Isracann is
working diligently with the Israeli partner to conclude the agreement for the
importation of Canadian products on an expedited basis. Additionally, Isracann
is finalizing an agreement with its Canadian partners to secure high-grade
genetic material for introduction into its Israeli-based genomics program.
While regional strains have certain inherently excellent traits, Isracann aims
to broaden product diversity, and through expert agronomy to achieve a
selection of world-class offerings.
Isracann
CEO, Darryl Jones states, “We continue to push ahead on multiple fronts. From
product importation to new genetics programs on the one hand, today we also
celebrate our official approval as foreign owners in this exciting sector. Now
we can truly dig in to finalize matters and accelerate our efforts to fully
enter the commercial marketplace. We’ve been in communication with all the
relevant parties and now with the licensing in-place, a number of initiatives
will be triggered almost immediately and should result in an accelerated pace
towards revenue generation. We have to admit that we always thought the
pandemic would create a delay, and it could have been worse. In the meantime,
we have by no means been standing still and have used the opportunity to invest
in added value and develop our relations throughout the region. Once again we
thank our Israeli team of consultants and stakeholders who have proven to be
invaluable at representing our interests so effectively and who share our
vision for success.”
Canopy Growth
Corporation (TSX:
WEED) (NASDAQ:
CGC),
a world-leading diversified cannabis, CBD and vaporization device company, today
announced Southern Glazer's Wine & Spirits, the world's
pre-eminent distributor of beverage alcohol, as the distribution partner for
its U.S. portfolio of CBD-infused beverages. This partnership announcement
follows the recent launch of Quatreau – Canopy's first line of CBD-infused
beverages sold in the U.S market.
"Through
this groundbreaking partnership, we will leverage Southern Glazer's established
distribution network to bring our CBD beverage portfolio to retailers and
consumers across the U.S. market," said Julious Grant, Chief Commercial
Officer, Canopy Growth. "The leadership team at Southern Glazer's shares
our values, priorities, and future-forward view of the category. Together, we
are committed to creating an immediate strategic route to market for Canopy's
premium CBD beverages."
Southern
Glazer's will distribute Canopy Growth's CBD beverages, beginning with its
CBD-infused sparkling water brand Quatreau™, across seven states, with
additional states in the months to come. Southern Glazer's will be selling
Quatreau™ through its existing commercial infrastructure, including its
industry-leading Proof® e-commerce platform at sgproof.com. Canopy Growth is
one of the first U.S. CBD beverage producers to access the nationwide network
of a large-scale alcohol distributor to reach consumers across the U.S. at
mainstream retail stores. The agreement also showcases the benefits of the
company's strategic relationship with Constellation Brands, the global beverage
leader.
"This
agreement reinforces our consumer-focused approach to identifying emerging
growth areas where we can add value for our customers," said David
Chaplin, Chief Growth Officer, Southern Glazer's Wine & Spirits.
"There is strong consumer interest in the CBD-infused beverage category
and our distribution network is uniquely positioned to deliver the most
efficient and effective route-to-market for CBD suppliers and retail customers.
We're proud to align with Canopy Growth, a company well-positioned to lead this
product category with a portfolio of premium, highly desirable consumer
brands."
"Innovation
in the beverage industry like we are seeing from Canopy Growth brings new
energy to the marketplace and increases the level of consumer interest in all
our products," added John Wittig, Chief Commercial Officer, Southern
Glazer's Wine & Spirits. "We are excited to be adding Quatreau as the
first CBD-infused beverage in our portfolio."
Quatreau
sparkling water contains 20 mg of premium, U.S. grown hemp-based CBD, in four
refreshing flavors: Cucumber + Mint, Passion Fruit + Guava, Blueberry + Acai,
and Ginger + Lime. With an MSRP of $3.99 per 12-ounce can, Quatreau is a
functional zero-sugar drink that delivers a natural, low calorie beverage
alternative. The stateside launch follows the successful 2020 rollout of
Quatreau in Canada, where it is now the top-selling ready-to-drink CBD
beverage.
Once
again, today’s podcast is sponsored by Phyto
Extractions Inc. (CSE:XTRX), an
agricultural-scale cannabis extraction, distillation and product manufacturer
located in Langley, BC at its co-located Health Canada Licensed Standard
Processing (extraction, no cultivation), Sales (extracts, topicals, and
edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through
Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D
license amendment.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can
trade these stocks and other ideas on our site
using our list of top stock trading
apps including Robinhood , Acorn, Stash and others.
To
hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of
each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
You can't hold a good weed stock down (Nasdaq: CGC) (NASDAQ: TLRY) (NASDAQ: ACB)
You can't hold a good weed stock down (Nasdaq: CGC) (NASDAQ: TLRY) (NASDAQ: ACB) : You can't hold a good weed stock down (Nasdaq: CG...
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...